Ideaya Biosciences Announced Clinical Data For The IDE397 Phase 2 Monotherapy Expansion Dose In Methylthioadenosine Phosphorylase-deletion Urothelial And Non-small Cell Lung Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
Ideaya Biosciences announced promising clinical data for its IDE397 Phase 2 monotherapy in MTAP-deletion urothelial and non-small cell lung cancer patients, showing high response and disease control rates with minimal adverse effects.
July 08, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ideaya Biosciences announced positive clinical data for its IDE397 Phase 2 monotherapy in MTAP-deletion urothelial and non-small cell lung cancer patients, showing a 39% overall response rate and a 94% disease control rate with minimal adverse effects.
The positive clinical data, including high response and disease control rates with minimal adverse effects, is likely to boost investor confidence and positively impact the stock price of Ideaya Biosciences in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100